Eric Paul Krenning

Eric Paul Krenning's AcademicInfluence.com Rankings

Eric Paul Krenning

Philosophy

#4447

World Rank

#6960

Historical Rank

Logic

#1894

World Rank

#2761

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Eric Paul Krenning's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Eric Paul Krenning Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Eric Paul Krenning's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors (2017) (1823)
Gastroenteropancreatic neuroendocrine tumours. (2008) (1504)
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. (2008) (1295)
Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients (1993) (1120)
The role of somatostatin and its analogs in the diagnosis and treatment of tumors. (1991) (843)
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary (2011) (789)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site (2016) (758)
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN (1989) (613)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. (2005) (571)
Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. (1997) (533)
Somatostatin-receptor imaging in the localization of endocrine tumors. (1990) (529)
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. (1992) (420)
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. (2010) (407)
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate (2003) (401)
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. (1997) (400)
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. (2002) (399)
Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. (2001) (387)
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. (2005) (376)
The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism (1993) (375)
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020) (373)
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients (2001) (373)
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum (2016) (352)
Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults (2002) (346)
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors (2017) (338)
Peptide receptor imaging and therapy. (2000) (337)
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours (2004) (323)
Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. (1989) (321)
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. (2002) (319)
Peptide Receptor Radionuclide Therapy (2004) (317)
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine (2002) (299)
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. (2005) (294)
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. (2005) (291)
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. (2006) (289)
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals (2003) (284)
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. (2001) (281)
Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐Octreotide (1994) (274)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging (2017) (267)
Radiolabelling DOTA-peptides with 68Ga (2005) (261)
Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. (1997) (246)
Somatostatin receptor imaging. (2002) (246)
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. (2005) (241)
Lutetium-labelled peptides for therapy of neuroendocrine tumours (2012) (231)
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. (2018) (226)
Distribution of somatostatin receptors in normal and tumor tissue. (1990) (226)
Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications (1992) (224)
Determinants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents. (1997) (221)
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives (2001) (219)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs (2009) (219)
86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion (2003) (216)
Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. (1998) (215)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues (2017) (213)
Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. (2002) (212)
Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. (1999) (211)
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities (2003) (206)
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours (2007) (204)
Bone mineral density and nutritional status in children with chronic inflammatory bowel disease (1998) (202)
Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. (1990) (197)
ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas) (2016) (192)
[177Lu‐DOTA0,Tyr3]octreotate for somatostatin receptor‐targeted radionuclide therapy (2001) (190)
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. (2004) (189)
Candidates for peptide receptor radiotherapy today and in the future. (2005) (184)
Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. (1990) (183)
Identification of thyroid hormone transporters. (1999) (182)
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. (2010) (181)
NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus) (2010) (179)
The effect of etanercept on Graves' ophthalmopathy: a pilot study (2005) (179)
In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. (1991) (179)
Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy (1997) (173)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide (2009) (169)
Somatostatin and the immune and haematopoetic system; a review (1994) (164)
Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT? (2006) (164)
Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate (2011) (163)
Peptide-receptor radionuclide therapy for endocrine tumors (2009) (163)
(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. (2011) (161)
Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. (2005) (161)
Peak bone mineral density, lean body mass and fractures. (2010) (159)
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate (2009) (158)
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. (2006) (156)
Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. (2010) (151)
Ontogeny of iodothyronine deiodinases in human liver. (1998) (151)
Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. (2001) (149)
Thyroid Hormone Transport by the Heterodimeric Human System L Amino Acid Transporter. (2001) (149)
D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. (1997) (147)
Somatostatin‐receptor Scintigraphy in Gastroenteropancreatic Tumors (1994) (143)
Evaluation of a radiolabelled cyclic DTPA‐RGD analogue for tumour imaging and radionuclide therapy (2000) (142)
In vivo somatostatin receptor imaging in medullary thyroid carcinoma. (1993) (137)
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. (2001) (137)
Localisation and mechanism of renal retention of radiolabelled somatostatin analogues (2005) (135)
Somatostatin-receptor scintigraphy in primary breast cancer (1994) (132)
Tumor imaging and therapy using radiolabeled somatostatin analogues. (2009) (132)
Thyroxine and 3,3',5-triiodothyronine are glucuronidated in rat liver by different uridine diphosphate-glucuronyltransferases. (1991) (131)
Radiolabelled peptides for tumour therapy: current status and future directions (2003) (131)
The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle‐aged women: associations with serum lipids (1993) (129)
Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. (1996) (129)
Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues (2010) (128)
Somatostatin receptor: scintigraphy and radionuclide therapy. (1996) (128)
Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. (2000) (127)
Characteristics of active transport of thyroid hormone into rat hepatocytes. (1981) (123)
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin (2007) (123)
Rare Functioning Pancreatic Endocrine Tumors (2006) (122)
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors: The First US Phase 2 Experience (2014) (122)
Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. (2005) (121)
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours (2008) (120)
Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. (1998) (119)
Neuroendocrine tumours: the role of imaging for diagnosis and therapy (2014) (119)
Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. (2002) (118)
RAISED TOTAL THYROXINE AND FREE THYROXINE INDEX BUT NORMAL FREE THYROXINE A Serum Abnormality due to Inherited Increased Affinity of Iodothyronines for Serum Binding Protein (1979) (118)
In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. (1993) (118)
in vitro and in vivo detection of somatostatin receptors in human malignant lymphomas (1992) (117)
A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. (1993) (117)
Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesterified fatty acids. (1993) (116)
Deiodination of thyroid hormone by human liver. (1988) (116)
Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate (2016) (114)
Somatostatin analogue scintigraphy in carcinoid tumours (1993) (113)
Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. (1994) (113)
Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course (2015) (112)
Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy (1998) (109)
Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. (1992) (108)
Somatostatin analogue scintigraphy in granulomatous diseases (1994) (108)
In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. (1991) (108)
Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. (1999) (107)
Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. (2001) (105)
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. (2011) (105)
Decreased transport of thyroxine (T4), 3,3′‐5‐triiodothyronine (T3) and 3,3′,5′‐triiodothyronine (rT3) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs (1982) (103)
In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. (1992) (103)
In vitro detection of somatostatin receptors in human tumors. (1992) (103)
Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. (2016) (102)
Neuroendocrine tumors and somatostatin: imaging techniques. (2005) (100)
Preclinical and clinical studies of peptide receptor radionuclide therapy. (2010) (99)
The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease (1994) (99)
Somatostatin receptor imaging in patients with sarcoidosis (1998) (99)
Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. (2007) (98)
Regional Cerebral Blood Flow and Cerebrovascular Risk Factors in the Elderly Population (1998) (98)
Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results (2017) (98)
Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors (2010) (98)
Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. (1998) (97)
Octreotide scintigraphy for the detection of paragangliomas. (1993) (96)
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate (2008) (96)
Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides. (2011) (95)
“To Serve and Protect”: Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting (2014) (95)
Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. (1994) (93)
Tumour uptake of the radiolabelled somatostatin analogue [DOTA0,TYR3]octreotide is dependent on the peptide amount (1999) (91)
Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. (2002) (90)
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate (2015) (89)
Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. (1995) (87)
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy (2018) (86)
[111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? (1994) (86)
Somatostatin analogue scintigraphy of malignant lymphomas (1993) (85)
Evaluation of radiolabelled bombesin analogues for receptor‐targeted scintigraphy and radiotherapy (1999) (85)
Somatostatin receptors in malignant tissues (1990) (84)
New advances in peptide receptor radionuclide therapy. (2002) (84)
Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer (2003) (84)
Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. (2016) (83)
Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. (1999) (81)
Thyroxine plus low-dose, slow-release triiodothyronine replacement in hypothyroidism: proof of principle. (2004) (81)
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management (2016) (80)
Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. (2009) (80)
Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. (1996) (80)
Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. (2004) (79)
Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours (2001) (78)
Somatostatin analogue scintigraphy. A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. (1992) (78)
Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma (2000) (77)
Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. (2011) (77)
Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. (1999) (77)
Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours (2018) (76)
OctreoTherTM: Ongoing Early Clinical Development of a Somatostatin-Receptor-Targeted Radionuclide Antineoplastic Therapy (2000) (75)
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? (2011) (75)
Long-Term Effects of Growth Hormone Therapy on Bone Mineral Density, Body Composition, and Serum Lipid Levels in Growth Hormone Deficient Children: A 6-Year Follow-Up Study (2002) (74)
A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. (2004) (74)
Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. (1999) (74)
INHERITED THYROXINE EXCESS: A SERUM ABNORMALITY DUE TO AN INCREASED AFFINITY FOR MODIFIED ALBUMIN (1981) (74)
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT (2016) (74)
The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0* (2011) (73)
Effects of caloric deprivation on thyroid hormone tissue uptake and generation of low-T3 syndrome. (1986) (72)
Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. (1997) (72)
Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. (2003) (72)
A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues (2010) (71)
SPECT Study of Folate Receptor-Positive Malignant and Normal Tissues in Mice Using a Novel 99mTc-Radiofolate (2008) (71)
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. (2011) (70)
Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma (2009) (69)
Anticancer activity of targeted proapoptotic peptides. (2006) (69)
Pre‐clinical evaluation of [111In‐DTPA‐Pro1, Tyr4]bombesin, a new radioligand for bombesin‐receptor scintigraphy (1999) (69)
Metaiodobenzylguanidine and [ 111 In ] Octreotide Uptake in Benign and Malignant Pheochromocytomas * (2001) (68)
Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours (2007) (68)
Safety of dobutamine-atropine stress myocardial perfusion scintigraphy. (1998) (68)
A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. (1994) (66)
Neuroendocrine tumors. Peptide receptor radionuclide therapy. (2007) (66)
In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals (2006) (66)
Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. (2003) (65)
NETTER-1 Phase III: Progression-Free Survival, Radiographic Response, and Preliminary Overall Survival Results in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate. (2016) (65)
Carrier-mediated transport of thyroid hormone into rat hepatocytes is rate-limiting in total cellular uptake and metabolism. (1986) (65)
Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. (1994) (65)
Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. (2007) (64)
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity (2003) (64)
The value of octreotide scintigraphy in patients with lung cancer (1994) (63)
Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. (1994) (63)
Bone mineral density in children with acute lymphoblastic leukaemia. (1999) (62)
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. (2021) (61)
Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography/computed tomography. (2011) (60)
In vitro detection of somatostatin receptors in human tumors. (1992) (59)
111In-octreotide scintigraphy in oncology. (1992) (59)
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. (2012) (59)
Somatostatin Receptor Scintigraphy in Patients with Carcinoid Tumors (1996) (59)
In vitro and in vivo detection of somatostatin receptors in human malignant tissues. (1991) (58)
Estrogen Receptor α Gene Polymorphisms and Bone Mineral Density in Healthy Children and Young Adults (2004) (57)
Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands (1988) (57)
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study (2020) (57)
Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine (2017) (57)
Octreoscan radioreceptor imaging (2003) (55)
Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy (2012) (55)
111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy (2005) (55)
Pemetrexed Improves Tumor Selectivity of 111In-DTPA-Folate in Mice with Folate Receptor–Positive Ovarian Cancer (2008) (54)
Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. (2004) (53)
Cost-effectiveness analysis of somatostatin receptor scintigraphy. (1996) (53)
Radioiodinated somatostatin analog scintigraphy in small-cell lung cancer. (1991) (52)
Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. (2005) (52)
Comparison of dobutamine stress echocardiography and technetium-99m sestamibi single-photon emission tomography for the diagnosis of coronary artery disease in hypertensive patients with and without left ventricular hypertrophy (1997) (52)
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest (2019) (52)
Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. (2007) (51)
Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate (2007) (50)
Somatostatin receptor scintigraphy in non-medullary thyroid cancer. (1996) (50)
The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. (1996) (50)
Accuracy of dobutamine tetrofosmin myocardial perfusion imaging for the noninvasive diagnosis of transplant coronary artery stenosis. (2000) (49)
Anti‐proliferative effect of radiolabelled octreotide in a metastases model in rat liver (1999) (49)
No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia (2006) (49)
Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA. (1992) (49)
Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. (2005) (48)
99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo. (1998) (48)
Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. (1999) (48)
Uptake of triiodothyroacetic acid and its effect on thyrotropin secretion in cultured anterior pituitary cells. (1994) (48)
Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. (2004) (47)
Octreotide and Related Somatostatin Analogs in the Diagnosis and Treatment of Pituitary Disease and Somatostatin Receptor Scintigraphy (1993) (47)
Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer (2001) (47)
Active transport of iodothyronines into human cultured fibroblasts. (1987) (46)
Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. (2001) (46)
Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts (2011) (46)
Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer (2002) (46)
mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer. (2013) (46)
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors (2018) (45)
Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate. (2006) (45)
Somatostatin analogs for the treatment of neuroendocrine tumors (2011) (44)
Therapy-related hematological malignancies after peptide receptor radionuclide therapy with 177Lu-DOTA-Octreotate: Incidence, course & predicting factors in patients with GEP-NETs (2017) (44)
Different regulation of thyroid hormone transport in liver and pituitary: its possible role in the maintenance of low T3 production during nonthyroidal illness and fasting in man. (1996) (44)
Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. (1996) (43)
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney (2007) (43)
Transport of 3,5,3'-triiodothyronine into the perfused rat liver and subsequent metabolism are inhibited by fasting. (1992) (43)
In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. (1996) (43)
Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats (2008) (42)
Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr3]Octreotate (2013) (42)
Free thyroxine assessed with three assays in sera of patients with nonthyroidal illness and of subjects with abnormal concentrations of thyroxine-binding proteins. (1993) (42)
Somatostatin analogs in the treatment of acromegaly. (1992) (42)
Vitamin D Receptor Gene Polymorphism Predicts Height and Bone Size, Rather Than Bone Density in Children and Young Adults (2003) (42)
Visualization of the thymus by substance P receptor scintigraphy in man (1996) (41)
111In-octreotide scintigraphy in oncology. (1993) (41)
Impaired thyroxine and 3,5,3'-triiodothyronine handling by rat hepatocytes in the presence of serum of patients with nonthyroidal illness. (1995) (41)
Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas (1999) (41)
Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs (2006) (40)
Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours (2009) (40)
177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors : Results of the Phase III NETTER-1 Trial (2016) (40)
Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. (2004) (40)
Long-term prognostic value of dobutamine stress echocardiography compared with myocardial perfusion scanning in patients unable to perform exercise tests (2004) (40)
Perfusion and Contractile Reserve in Chronic Dysfunctional Myocardium: Relation to Functional Outcome After Surgical Revascularization (2002) (40)
Dynamic and Static Small-Animal SPECT in Rats for Monitoring Renal Function After 177Lu-Labeled Tyr3-Octreotate Radionuclide Therapy (2010) (40)
Pulmonary clearance of 99mTc‐DTPA during halothane anaesthesia (1990) (39)
Uptake of thyroxine in cultured anterior pituitary cells of euthyroid rats. (1994) (39)
Inhibition of iodothyronine transport into rat liver cells by a monoclonal antibody. (1986) (39)
Somatostatin receptor scintigraphy useful in stage I–II Hodgkin's disease: more extended disease identified (2001) (38)
Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy (1995) (38)
Somatostatin and the concept of peptide receptor scintigraphy in oncology. (1994) (38)
Estrogen receptor alpha gene polymorphisms and bone mineral density in healthy children and young adults. (2004) (38)
Anti‐tumor effect and increased survival after treatment with [177Lu‐DOTA0,Tyr3]octreotate in a rat liver micrometastases model (2003) (37)
Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats (2007) (37)
Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy (2000) (37)
The clinical use of somatostatin analogues in the treatment of cancer. (1990) (37)
Expression of rat liver cell membrane transporters for thyroid hormone in Xenopus laevis oocytes. (1997) (36)
Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. (2004) (36)
Transport of thyroxine into cultured hepatocytes: effects of mild non‐thyroidal illness and calorie restriction in obese subjects (1994) (36)
Echocardiographic and radionuclide pulmonary blood flow patterns after transcatheter closure of patent ductus arteriosus. (1996) (36)
Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability. (2003) (36)
Endocrine Gastroenteropancreatic Tumors (2005) (35)
In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand (1996) (35)
Radiolabelled regulatory peptides for imaging and therapy. (2007) (34)
Clinical applications of somatostatin analogs (1990) (34)
Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors. (1993) (34)
The role of radioactive somatostatin and its analogues in the control of tumor growth. (2000) (34)
Uptake of 3,3',5,5'-tetraiodothyroacetic acid and 3,3',5'-triiodothyronine in cultured rat anterior pituitary cells and their effects on thyrotropin secretion. (1995) (34)
Preoperative comparison of different noninvasive strategies for predicting improvement in left ventricular function after coronary artery bypass grafting. (2003) (34)
Single photon emission computed tomography in patients with acute hydrocephalus or with cerebral ischaemia after subarachnoid haemorrhage. (1991) (34)
Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. (2007) (34)
Causes and effects of the low T3 syndrome during caloric deprivation and non-thyroidal illness: an overview. (1988) (33)
Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. (2004) (33)
The visualization of gastroenteropancreatic endocrine tumors. (1993) (33)
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. (2021) (33)
From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging. (2007) (33)
Nephrotoxicity in Mice After Repeated Imaging Using 111In-Labeled Peptides (2010) (33)
Bone Mineral Density and Body Composition in Adolescents with Childhood-Onset Growth Hormone Deficiency (2009) (33)
Safety, hemodynamic profile, and feasibility of dobutamine stress technetium myocardial perfusion single-photon emission CT imaging for evaluation of coronary artery disease in the elderly. (2000) (33)
Accuracy of exercise stress technetium 99m sestamibi SPECT imaging in the evaluation of the extent and location of coronary artery disease in patients with an earlier myocardial infarction (2000) (33)
Transport and metabolism of iodothyronines in cultured human hepatocytes. (1993) (32)
Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. (2002) (32)
Vascular risk factors, atherosclerosis, cerebral white matter lesions and cerebral perfusion in a population-based study (1996) (31)
Androgen‐regulated gastrin‐releasing peptide receptor expression in androgen‐dependent human prostate tumor xenografts (2010) (31)
Evidence that the uptake of tri-iodo-L-thyronine by human erythrocytes is carrier-mediated but not energy-dependent. (1982) (31)
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. (2005) (30)
Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. (2017) (30)
Thyroid hormone transport by the heterodimeric human system L amino acid transporter. (2001) (30)
Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function (2009) (30)
Bone mineral density, growth, and thyroid function in long-term survivors of pediatric Hodgkin's lymphoma treated with chemotherapy only. (2009) (30)
Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog (1990) (30)
Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. (2003) (30)
99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy? (2003) (29)
Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: the role of a coordinator for quality control. (2000) (28)
The relation between 25-hydroxyvitamin D with peak bone mineral density and body composition in healthy young adults (2011) (28)
Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs. (1990) (28)
Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview (1997) (28)
Somatostatin receptors and breast cancer. (1998) (28)
Plasma membrane transport of thyroid hormone: its possible pathophysiological significance (1983) (28)
Evidence for carrier-mediated uptake of triiodothyronine in cultured anterior pituitary cells of euthyroid rats. (1993) (27)
Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting. (2015) (27)
Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? (2006) (27)
Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide. (1994) (27)
Octreotide scintigraphy in thyroidal and orbital Graves' disease. (1998) (26)
The significance of plasma membrane transport in the bioavailability of thyroid hormone. (1998) (26)
A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide (1994) (26)
A pragmatic perspective on molecular targeted radionuclide therapy. (2005) (26)
Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy. (2007) (26)
Somatostatin receptor imaging of endocrine gastrointestinal tumors. (1992) (25)
Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues (2009) (25)
[99mTc]Demotate 2 in the detection of sst2-positive tumours: a preclinical comparison with [111In]DOTA-tate (2006) (25)
HYPERTHYROXINAEMIA DUE TO DECREASED PERIPHERAL TRIIODOTHYRONINE PRODUCTION (1982) (25)
Decreased peripheral 3,5,3'-triiodothyronine (T3) production from thyroxine (T4): a syndrome of impaired thyroid hormone activation due to transport inhibition of T4- into T3-producing tissues. (1993) (25)
Radiotherapy of severe ophthalmic Graves’disease (1985) (25)
Inhibition of uptake of thyroid hormone into rat hepatocytes by preincubation with N-bromoacetyl-3,3',5-triiodothyronine. (1988) (25)
Receptor imaging in the diagnosis and treatment of pituitary tumors (1999) (25)
Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats. (2007) (25)
Dobutamine stress echocardiography and technetium-99m-tetrofosmin/fluorine 18-fluorodeoxyglucose single-photon emission computed tomography and influence of resting ejection fraction to assess myocardial viability in patients with severe left ventricular dysfunction and healed myocardial infarction. (1999) (25)
[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study (2012) (24)
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. (2018) (24)
Regulation of hormone release by cultured cells from a thyrotropin-growth hormone-secreting pituitary tumor. Direct inhibiting effects of 3, 5, 3′-triiodothyronine and dexamethasone on thyrotropin secretion (1984) (24)
Regulation of influx and efflux of thyroid hormones in rat hepatocytes: possible physiologic significance of the plasma membrane in the regulation of thyroid hormone activity. (1984) (23)
Somatostatin receptor scintigraphy in the initial staging of Hodgkin's disease (1996) (23)
Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. (2000) (23)
Transantral orbital decompression for Graves' disease. (1994) (23)
Reduction of Renal Uptake of Radiolabeled Octreotate by Amifostine Coadministration (2012) (23)
Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs. (2007) (22)
Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. (2005) (22)
Prognostic implications of a normal stress technetium-99m-tetrofosmin myocardial perfusion study in patients with a healed myocardial infarct and/or previous coronary revascularization. (2006) (22)
The relevance of somatostatin receptor expression in malignant lymphomas. (1996) (22)
Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation (2016) (22)
Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys. (2007) (22)
Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors (1992) (21)
Effects of a furan fatty acid and indoxyl sulfate on thyroid hormone uptake in cultured anterior pituitary cells. (1995) (21)
Effects of immunoscintigraphy with monoclonal antibodies in assays of hormones and tumour markers. (1989) (21)
The role of octreotide scintigraphy in rheumatoid arthritis and sarcoidosis. (2003) (21)
[(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy. (2014) (21)
Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide (1998) (21)
Dopamine-producing paraganglioma not visualized by iodine-123-MIBG scintigraphy. (1995) (21)
Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin. (2018) (21)
Different effects of amiodarone on transport of T4 and T3 into the perfused rat liver. (1994) (20)
Phase I study of therapy with Y-90-SMT487 (octreother) in patients with somatostatin receptor (SS-R) positive tumors. (2002) (20)
Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+. (2004) (20)
Efficacy of Percutaneous Intramyocardial Injections Using a Nonfluoroscopic 3-D Mapping Based Catheter System (2002) (20)
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide (2008) (20)
T4 uptake into the perfused rat liver and liver T4 uptake in humans are inhibited by fructose. (1994) (20)
Current tools in the diagnosis of pituitary tumours. (1993) (20)
Somatostatin receptor imaging and therapy of pancreatic endocrine tumors. (1999) (19)
FDG SPECT in the assessment of myocardial viability. Comparison with dobutamine echo. (1997) (19)
Diagnostic imaging of dopamine receptors in pituitary adenomas. (2007) (19)
Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide (1993) (19)
Assessment of cerebral perfusion with single-photon emission tomography in normal subjects and in patients with Alzheimer's disease: effects of region of interest selection (1994) (19)
Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions (2012) (19)
Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene. (2004) (19)
Somatostatin and its cyclic octapeptide analog SMS 201-995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia. (1995) (19)
Collagen Ia1 Polymorphism is Associated with Bone Characteristics in Caucasian Children and Young Adults (2002) (19)
Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity (2002) (18)
Liver and Vertebral Uptake of Tc-99m Macroaggregated Albumin (MAA) (2004) (18)
Development and use of a mathematical two-pool model of distribution and metabolism of 3,3',5-triiodothyronine in a recirculating rat liver perfusion system: albumin does not play a role in cellular transport. (1990) (18)
Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats. (1998) (17)
Graft regeneration and host liver atrophy after auxiliary heterotopic liver transplantation for chronic liver failure (1992) (17)
Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotide. (2005) (17)
Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives (2011) (17)
The visualization of gastroenteropancreatic endocrine tumors. (1992) (17)
Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. (2005) (17)
Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy (1996) (16)
Use of Radiolabeled Somatostatin to Localize Islet Cell Tumors (1994) (16)
99mTc Radiotracers Based on Human GRP(18-27): Synthesis and Comparative Evaluation (2013) (16)
Feasibility and image quality of dual-isotope SPECT using 18F-FDG and (99m)Tc-tetrofosmin after acipimox administration. (2003) (16)
Endocrine aspects of the diagnosis and treatment of primary brain tumours (1992) (15)
Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon. (2016) (15)
Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy (2000) (15)
[111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors. (2014) (15)
Long-term prognostic value of dobutamine stress echocardiography compared with myocardial perfusion scanning in patients unable to perform exercise tests. (2004) (15)
Comparison of uptake of99mTc-MIBI,99mTc-tetrofosmin and99mTc-012 into human breast cancer cell lines (1996) (15)
Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948. (2004) (15)
Comparison of uptake of 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 into human breast cancer cell lines. (1996) (15)
CELLULAR AND HUMORAL IMMUNITY IN PATIENTS WITH HYPERTHYROID GRAVES' DISEASE BEFORE, DURING AND AFTER ANTITHYROID DRUG TREATMENT (1987) (15)
Uptake and metabolism of 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine by human liver-derived cells: HepG2 cells as a model for thyroid hormone handling by human liver. (1996) (14)
Studies on radiolabeled somatostatin analogues in rats and in patients. (1996) (14)
Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [Lu-DOTA,Tyr]octreotate (2004) (14)
The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth (2004) (14)
The kinetics of thyroid hormone transporters and their role in non-thyroidal illness and starvation. (2007) (13)
Functional assessment of ALCAPA syndrome by dobutamine stress thallium-201 SPECT and echocardiography. (1996) (13)
(99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice. (2016) (13)
Receptor imaging of human diseases using radiolabeled peptides. (1995) (13)
Slaging of Sézary syndrome with somatostatin receptor scintigraphy (1996) (13)
SPECIFIC THYROXINE BINDING ALBUMIN IS A CONSTITUENT OF NORMAL HUMAN SERUM (1984) (13)
Pitfalls in the interpretation of thyroid function tests in old age and non-thyroidal illness. (1987) (13)
Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma. (1989) (13)
In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands. (2015) (13)
Endocrine-Related Cancer ( 2010 ) 17 R 53 – R 73 Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors (2010) (12)
Relation between QT dispersion and myocardial viability in ischemic cardiomyopathy. (2003) (12)
Rapid sulfation of 3,3',5'-triiodothyronine in native Xenopus laevis oocytes. (1998) (12)
High serum levels of the thyrotropin-releasing hormone-like peptide pyroglutamyl-glutamyl-prolineamide in patients with carcinoid tumors. (1996) (12)
Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors (1993) (12)
in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (2006) (12)
Tumor diagnosis with new 111In-radioligands based on truncated human gastrin releasing peptide sequences: synthesis and preclinical comparison. (2013) (12)
772-2 Local Intracoronary Delivery of Heparin and of a Somatostatin Analogue (Octreotide) Following Angioplasty in Man: Evaluation of Efficacy of Delivery by Radio-Isotopic Technique (1995) (12)
Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study (2001) (12)
In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas. (2003) (11)
Changes in renal tri-iodothyronine and thyroxine handling during fasting. (2000) (11)
Erratum: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors (Neuroendocrinology (2004) 80 (394-424)) (2005) (11)
Inhibition of kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine? (2006) (11)
In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice. (2014) (11)
Therapeutic use of radiolabelled peptides. (2000) (10)
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours (2021) (10)
[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting. (2014) (10)
Adaptive changes in transmembrane transport and metabolism of triiodothyronine in perfused livers of fed and fasted hypothyroid and hyperthyroid rats. (1994) (10)
Targeted radiotherapy with Y-90-DOTA-TYR3-octreotide (Y-90-SMT487; OctreoTher (TM)): A phase I study. (2000) (10)
Hepatobiliary handling of iodine-125-Tyr3-octreotide and indium-111-DTPA-D-Phe1-octreotide by isolated perfused rat liver. (1993) (10)
Uptake of triiodothyronine sulfate and suppression of thyrotropin secretion in cultured anterior pituitary cells. (1994) (10)
A case of antibody formation against octreotide visualized with 111In‐octreotide scintigraphy (1993) (10)
Replacement therapy with L-thyroxine: serum thyroid hormone and thyrotropin levels in hypothyroid patients changing from desiccated thyroid to pure thyroxine substitution therapy. (1981) (9)
[DOTA,Tyr3]octreotate, labeled with 177Lu, is most promising for radionuclide therapy of somatostatin receptor-positive tumors (2000) (9)
Impact of diabetes mellitus on prediction of clinical outcome after coronary revascularization by 18F-FDG SPECT in patients with ischemic left ventricular dysfunction. (2006) (9)
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE (2021) (9)
DOTA‐NOC, A high affinity ligand of the somatostatin receptor subtypes 2, 3 and 5 for radiotherapy (2001) (9)
Reduced T3 deiodination by the human hepatoblastoma cell line HepG2 caused by deficient T3 sulfation. (1993) (9)
Somatostatin receptor imaging with 123I-Tyr3-Octreotide. (1990) (9)
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms (2018) (9)
Somatostatin receptor scintigraphy (SSRS) in GEP-tumors (1997) (9)
Phase 1 study of peptide receptor radionuclide therapy (PRRT) with [Y-90-DOTA,Tyr(3)]octreotide in patients with somatostatin receptor positive tumors (2003) (8)
Euro-Collins Solution Versus Uw-Solution for Long-Term Liver Preservation in the Isolated Rat-Liver Perfusion Model (1991) (8)
Three-compartmental analysis of effects of D-propranolol on thyroid hormone kinetics. (1988) (8)
The role of somatostatin analogs in the control of tumor growth. (1994) (8)
[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate. (2006) (8)
Somatostatin-receptor scintigraphy in Graves' orbitopathy (1996) (8)
NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE. (2016) (8)
Tumor dosimetry based on PET Y-86-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to Y-90-SMT487 (OctreoTher (TM)) therapy. (2000) (8)
Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats. (1997) (7)
The Inhibitory Effect of 111In-DTPA0-Octreotide on Intrahepatic Tumor Growth After Partial Hepatectomy (2002) (7)
Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair (2019) (7)
Radiolabeling DOTA-Peptides with 90Y and 177Lu to a High Specific Activity (2016) (7)
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling (2021) (7)
[Diagnosis and treatment of differentiated thyroid carcinoma]. (1989) (7)
Somatostatin Receptor Gene Therapy Combined With Targeted Therapy With Radiolabeled Octreotide: A New Treatment for Liver Metastases (2002) (7)
Peptide receptor scintigraphy (PRS) with In-111-DOTANOC and peptide receptor radionuclide therapy (PRRT) with Lu-177-DOTANOC (2007) (7)
Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability. (2019) (7)
Phase I Study of Peptide Receptor Radionuclide Therapy With (lllIn-DTPA~ (2002) (7)
Dobutamine stress thallium-201 single-photon emission tomography versus echocardiography for evaluation of the extent and location of coronary artery disease late after myocardial infarction (1999) (7)
NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis (2016) (6)
Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy. (2002) (6)
Metabolic effects of amino acids (AA) solutions infused for renal radioprotection. (2000) (6)
Nuclear medicine imaging of breast cancer. (1996) (6)
Regulation of thyroid hormone bioactivity. (1986) (6)
Can In-111-DTPA-octreotide (In-oC) predict kidney and tumor exposure during treatment with Y-90-SMT487 (OctreoTher (TM))? (2000) (6)
[99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models (2020) (6)
Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses (2019) (6)
Collagen Ialpha1 polymorphism is associated with bone characteristics in Caucasian children and young adults. (2002) (6)
Detection of myocardial viability with F-18-fluorodeoxyglucose and single photon emission computed tomography. (1997) (6)
Tumour therapy with radiolabelled peptides: current status and future directions (2004) (5)
Peptide receptor radionuclide therapy (PRRT) with Y-90-DOTA(0),Tyr(3)-octreotide (Y-Oc) and In-111-DTPA(0)-octreotide (In-Oc): Comparison of tumor response and toxicity. (2002) (5)
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method (2006) (5)
Somatostatin receptor scintigraphy in cutaneous malignant lymphomas. (1996) (5)
Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study. (2018) (5)
Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors. (2007) (5)
Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate (2013) (5)
Are GRP-receptors present in the human pancreas? (2006) (5)
Anaphylactoid reaction from amifostine. (2007) (5)
Peptides for Radionuclide Therapy (2008) (4)
Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors (2018) (4)
Optimizing the Profile of [99mTc]Tc–NT(7–13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors (2020) (4)
Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands (2020) (4)
Severe ophthalmic Graves' disease and autoimmune thyroid disorders with different clinical expression. (1983) (4)
Autoimmunity of thyroid disease. With emphasis on Graves' disease. (1985) (4)
Strategy of thyroid-function testing, a comparative study using TT4, FT4I, various FT4 and IRMA-TSH kits. (1986) (4)
Clinical and radio-diagnostic aspects in the evaluation of thyroid nodules with respect to thyroid cancer. (1988) (4)
177Lu-Dotatate for Midgut Neuroendocrine Tumors (2017) (4)
Effect of omeprazole on renal uptake of 111-In-DTPA-octreotide (2001) (4)
Amino acid (AA) solutions infused for renal radioprotection: Metabolic effects (2000) (4)
Targeted radiotherapy of neuroendocrine tumors using Lu-177-DOTA octreotate with prolonged intervals (2007) (4)
PET/CT imaging with a novel 68Ga-labelled GRP-receptor antagonist, Sarabesin 3. First clinical data in patients with prostate and breast cancer (2013) (4)
Peptide Receptor Radionuclide Therapy: Preclinical Findings (2016) (4)
Kidney protection during peptide receptor radionuclide therapy (PRRT) (2009) (4)
Site-specific intravascular administration of drugs: history of a method applicable in humans. (1997) (4)
The Role of Octreotide Scintigraphy in Clinical Diagnosis and Therapy (1996) (3)
A Blood-Based Multi-Transcript Test - the NETest - Predicts and Defines the Efficacy of Peptide Radio Receptor Therapy in Neuroendocrine Tumors (2016) (3)
Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. (2018) (3)
Effects of d-Propranolol Treatment on Transport of Thyroid Hormones into Tissue Cells (1986) (3)
Tc-99m sestamibi before and during treatment in a patient with sarcoidosis and persistent hyperparathyroidism. (2000) (3)
Salvage therapy with 177Lu-octreotate in patients with gastroenteropancreatic neuroendocrine tumors (2009) (3)
Clinical Practice of Molecular Radiotherapy (2007) (3)
Somatostatin Receptor Targeted-Radio-Ablation of Tumors (2004) (3)
Thyroid Hormone-Binding Plasma Proteins (1986) (3)
Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE : The NETTER-1 phase III trial (2017) (3)
Effects of quenchers on the radiochemical purity of 111In-labeled peptides (2007) (3)
EUTHYROID HIGH TOTAL T4, NORMAL T3 SYNDROME (1979) (3)
Takayasu's arteritis. Case report and review of the literature. (1984) (3)
One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in Mice Treated with Entresto (2020) (3)
Effect of peptide amount on biodistribution of Y-86-DOTA-Tyr(3)-octreotide (SMT487). (2000) (3)
[68Ga]NeoBomb1, a new potent GRPR-antagonist for PET imaging - Preclinical and first clinical evaluation in prostate cancer (2016) (3)
Reduction of 68Ge activity containing liquid waste from 68Ga PET chemistry in nuclear medicine and radiopharmacy by solidification (2010) (3)
Somatostatin Receptor Imaging in Oncology (1999) (3)
Assessment of myocardial viability by dobutamine stress echo and simultaneous Tc99m-Tetrofosmin/18-flurodeoxy-glucose SPECT (1997) (2)
Peptide receptor imaging (2006) (2)
131I therapy for thyrotoxicosis towards 2000 (1996) (2)
The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy. (2002) (2)
Chapter 17 - Somatostatin (1997) (2)
EUTHYROID HIGH TOTAL T4, NORMAL T3 SYNDROME (1979) (2)
Somatostatin Receptors in Gastroenteropancreatic Tumors (1996) (2)
The significance of plasma membrane transport of iodothyronines in the regulation of thyroid hormone bioavailability. (1988) (2)
EANM Abstracts 2013 (2013) (2)
1165TiPNETTER-1: FIRST PIVOTAL PHASE III STUDY EVALUATING 177LU-DOTATATE IN MIDGUT NEUROENDOCRINE TUMOURS. (2014) (2)
Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population (2019) (2)
Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. (2017) (2)
Diffuse lung and stomach uptake of Tc-99m oxidronate (HDP). (2003) (2)
Octreotide agent shows peptide imaging potential. (1993) (2)
A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide (2004) (2)
In vivo somatostatin receptor imaging in lung cancer (1991) (2)
Site-Specific Intracoronary Delivery of Octreotide in Humans: A Pharmacokinetic Study to Determine Dose-Efficacy in Restenosis Prevention (2004) (2)
[The role of radioactive iodine in the treatment of hyperthyroidism]. (1986) (2)
In vivo enzyme inhibition - A new promising route toward higher diagnostic sensitivity and therapeutic efficacy of tumor-directed radiopeptides (2014) (2)
Planar cobalt-57 bleomycin scintigraphy compared with CT-scan in the diagnosis and staging of lung cancer. (1994) (2)
Refractory immune-mediated and haematological diseases: candidates for peptide receptor radiotherapy? (2000) (2)
An unusual case of multiple endocrine neoplasia type 1 and the role of 111In-pentetreotide scintigraphy. (1996) (2)
Biodistribution of yttrium and lutetium labeled DOTATOC and DOTATATE in rat tumor models. (2002) (2)
Congenital hypothyroidism and partial thyroid hormone unresponsiveness of the pituitary in a patient with congenital thyroxine binding albumin elevation (1989) (1)
Prediction of functional outcome after revascularization by serial dual-isotope Tc-99m-Tetrofosmin and 18-FDG SPECT and dobutamine stress echo in patients with severe LV dysfunction (1999) (1)
[Insulinoma and octreotide]. (1992) (1)
[111In-DTPA-D-Phe1]-Octreotide (SDZ 215-811) to image somatostatin receptor positive tumors (1992) (1)
Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy. (2018) (1)
Prognostic value of dobutamine-atropine sestamibi imaging (1996) (1)
Radiopeptide antagonists for imaging and therapy of GRPR+ tumors (2011) (1)
Peptide Receptor Radionuclide Therapy in Patients with Somatostatin Receptor‐Positive Neuroendocrine Tumors (2010) (1)
The utility of blood-based molecular tools-the NETest-to monitor and evaluate the efficacy of PRRT in neuroendocrine tumors. (2020) (1)
99mTc-Demogastrin 2 for CCK 2-receptor scintigraphy in medullary thyroid carcinoma (2008) (1)
Peptides and monoclonal antibodies in oncology: an introduction. (2003) (1)
Procedure Guideline for Somatostatin Receptor (2001) (1)
[Receptor scintigraphy with somatostatin analog in oncology]. (1990) (1)
Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney? (2005) (1)
Comparison of [111In]SAR-G2 and 3 in GRPR+ cells and animal models (2010) (1)
The effect of etanercept on Graves' ophthalmopathy: (2005) (1)
Peptide receptor radionuclide therapy (PRRT) with [IN-111-DTPA0]octreotide (In-111-0C) in rats bearing the pancreatic somatostatin receptor (SSR) positive tumor CA20948 (1997) (1)
NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors (2017) (1)
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors (2018) (1)
Diagnostic and Predictive Value of Axial and Coronal Spect with Technetium-99m Labelled D,L-Hexamethyl-Propylene Amine Oxime (99mTC HM-PAO) in Patients with Normal Pressure Hydrocephalus Syndrome (NPH) (1993) (1)
Auxiliary partial liver transplantation: imaging evaluation in 10 patients. (1989) (1)
Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions (2012) (1)
Radiolabelled bombesin analogs in preclinical studies (2007) (1)
Thyroid hormone uptake by rat hepatocytes in primary culture (1983) (1)
Acipimox is effective to promote the uptake of glucose in myocardial SPECT with 18-FDG (1997) (1)
Sandostatin® LAR® Leaders Meeting – European Neuroendocrine Tumour Network ENET (2000) (1)
Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA,Tyr3]octreotide: Toxicity and efficacy of 4-cycle and single-cycle regimens. (2004) (1)
Transport of Thyroid Hormone (TH) into Hepatocytes (1989) (1)
[Comparison of the usual thyroid function tests with more recent TSH tests in patients with non-thyroid related diseases]. (1987) (1)
Somatostatin receptors and cancer (1993) (1)
Blood measurements of neuroendocrine tumor (NET) transcripts and gene cluster analysis to predict efficacy of peptide radioreceptor therapy. (2017) (1)
Phosphoramidon enhances tumor uptake of truncated [111In-DOTA]gastrins (2014) (1)
Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study (2022) (1)
Euthyroid high total T4, normal T3 syndrome. (1979) (1)
Transporter proteins specific for thyroid hormones and their agonists and antagonists (1998) (0)
The hypereosinophilic syndrome. (1982) (0)
Obituary of Professor T.J. Visser (2018) (0)
Receptor imaging in the diagnosis and treatment of pituitary tumors (1999) (0)
Subject Index Vol. 80, 2004 (2005) (0)
Nuclear medicine techniques for the t of neuroendocrine tumours (2011) (0)
The role of megalin in the renal uptake of radiolabeled peptides (2009) (0)
Imaging Techniques and Existing Agents (1999) (0)
Peptide radionuclide receptor therapy (PRRT) with Lu-177-DOTA, Tyr3-octreotate (LuTATE): Risk factors, radiation dose and BED, impact on long-term renal toxicity (2010) (0)
Safetyof Dobutamine-Atropine Stre ss Myocardial Perfusion Scintigraphy (1998) (0)
[Choice of time of surgery in the surgical rehabilitation of Graves' ophthalmopathy]. (1992) (0)
tiroactiva controlled release composition. (1992) (0)
Abstract 3106: A blood-based neuroendocrine tumor multi-transcript test predicts and defines PRRT efficacy in neuroendocrine tumors (2016) (0)
Circulating neuroendocrine transcripts and gene cluster analysis to predict the efficacy of peptide radioreceptor therapy. (2016) (0)
Recurrence of phaeochromocytoma, with development of metastases. Effect of treatment with alpha-methylparatyrosine. (1981) (0)
Therapeutic use of somatostatinpeptiden (1991) (0)
Circulating neuroendocrine tumor gene expression is effective in monitoring peptide receptor radionuclide (PRRT) efficacy (2018) (0)
[No further use of desiccated thyroid gland]. (1983) (0)
[The effect of aging on thyroid hormone metabolism and its clinical implications]. (1986) (0)
Comparison of dobutamine stress echocardiography and 201thallium SPECT in the evaluation of the extent of coronary artery disease after myocardial infarction (1999) (0)
Bone marrow dosimetry after [Lu-177-DOTA0,Tyr3]octreotate (2009) (0)
20. Sensitivity of Captopril renography for detecting renal artery stenosis based on visual judgement of sequential images performed with 99Tcm-MAG3 (1992) (0)
Peptide receptor radionuclide therapy (PRRT) with OctreoScan in a rat liver tumour model after partial hepatectomy: Simulation of a clinical situation (2000) (0)
Survival in patients with neuroendocrine tumors after treatment with [Y-90-DOTA,Tyr(3)]octreotide in a phase-1 study. (2003) (0)
SPECT/CT of viral distribution and gene expression in vivo following intratumoral injection of directly radiolabeled adenoviruses (2007) (0)
Subject Index Vol. 11, 1994 (1994) (0)
D-lysine for reduction of renal[in-111-DTPA,D-phe-1 ]-octreotide and [Y-90-DOTA,D-phe-1,tyr-3]octreotide uptake (1997) (0)
Letter to the Editor (2003) (0)
Integrated Medical Communication and Retrieval Sytem: Patient (1990) (0)
A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabine (2018) (0)
Contents Vol. 71, 2009 (2009) (0)
Somatostatin peptides, their analogues or derivatives, to processes for their preparation and pharmaceutical compositions containing them (1989) (0)
Transplantation: Imaging Evaluation in 10 Patients (1989) (0)
The effects of bisoprolol and propanolol on symptoms and thyroid function in hyperthyroidism: a comparative study (1995) (0)
[The significance of thyroglobulin determination in the follow-up of patients with papillary or follicular thyroid carcinoma]. (1989) (0)
Small animal SPECT/CT for in vivo evaluation of radiotracers (2007) (0)
Thyreoaktiv composition having sustained-release (1992) (0)
The comparison of somatostatin receptor and 67-gallium scintigraphy in the staging of malignant lymphomas (1997) (0)
Effects of the antifolate pemetrexed on radiofolate uptake and distribution in FR-positive tumors and kidneys (2007) (0)
1 2 Animal SPECT imaging with multi-pinhole apertures and fusion with MRI (0)
In Memoriam – Prof. Dr. Georg Hennemann, Internist (1932–2018) (2019) (0)
Consensus assessment : Imaging and Biomarkers in Gastroenteropancreatic 1 Neuroendocrine Tumour Disease Management (2016) (0)
SP-0570: Neuroendocrine tumours - personalised diagnosis and treatment using radiolabelled peptides (2016) (0)
Somatostatin Receptor Imaging for Temporal Paragangliomas: A Simple and Sensitive Localization Technique (1994) (0)
Is it possible to predict renal function in small animals using a multi-pinhole SPECT system. (2007) (0)
13 SOMATOSTATIN RECEPTOR IMAGING (0)
AbstractMonday AM, April 24Myocardial perfusion scintigraphy for evaluation of ST-segment elevation during dobutamine stress test in patients with myocardial infarction (1995) (0)
Thyroaktive controlled release composition (1992) (0)
FreeThyroxineAssessedwithThreeAssaysin Sera of Patientswith Nonthyroidal Illnessand of SubjectswithAbnormalConcentrations of Thyroxine-Binding Proteins (1993) (0)
Amifostine reduces toxicity of targeted radionuclide therapy without affecting anti-tumor effects (2007) (0)
307 DETECTION OF EARLY COMPARTMENTAL DEGENERATIVE CHANGES IN A RAT MODEL FOR OA USING HIGH RESOLUTION MULTI PINHOLE SPECT-CT (2007) (0)
Somatostatin receptors in apudomas: A physiological basis for therapy and a diagnostical tumour marker (1989) (0)
Somatostatin Receptor Scintigraphy: Blazing in Indium and Quenching in Gallium (2020) (0)
Radioiodinated SomatostatinAnalog Scintigraphy in Small-CellLung Cancer (1991) (0)
The Role of Somatostatin Receptor Scintigraphy in Gastroenteropancreatic Endocrine Tumors (1994) (0)
[Nodules in the thyroid gland]. (1985) (0)
Diagnosis and treatment of thyroid malfunction in The Netherlands. (1989) (0)
Comparison of 1!1In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy1 (2006) (0)
Somatostatin Receptor Scintigraphy in Thyroidal Diseases (2000) (0)
[The effect of immunoscintigraphy with monoclonal antibodies on assays of hormones and tumor markers. This is not the end of the matter!]. (1989) (0)
Metabolic stability and tumor uptake improvements via an ABD-arm in [99mTc]Tc-DT10: first preclinical experiences in pancreatic cancer models (2022) (0)
Metastasis after mTOR inhibition by RAD001 in a neuroendocrine rat tumor model: Combination therapy with 177Lu-DOTA,Tyr3-octreotate (2011) (0)
PRRT neuroendocrine tumor response assessment using blood transcript analysis: The NETest. (2020) (0)
Subject Index, Vol. 26, 1987 (1987) (0)
Subject Index Vol. 71, 2009 (2009) (0)
Biological profile of 111In-SB9, a new GRPR-antagonist radioligand for prostate cancer imaging: the role of neprilysin on tumor targeting efficacy in mice (2019) (0)
Subject Index, Vol. 54, Supplement 1, 1993 (1993) (0)
Effects of Gly11/DAla11-replacement in GRPR-antagonist based radioligands (2014) (0)
Potential use of OctreoScan-111 to predict kidney exposure during 90Y-SMT487 therapy (2000) (0)
The Role of Somatostatin Receptors in the Diagnosis and Therapy of Cancer (1993) (0)
Somatostatin Analogues and Radionuclides Used in Therapy (2015) (0)
A predictive quotient index, comprising neuroendocrine gene cluster analysis in blood and tissue grading is specifically predicts PRRT efficacy (2017) (0)
[Fewer thyroid operations in The Netherlands]. (1989) (0)
Somatostatin receptor scintigraphy for the initial staging of non-Hodgkin's lymphomas (1997) (0)
Development and preliminary evaluation of a new multi-slit collimator for the LinoView rodent SPECT system (2007) (0)
Scintigraphy of Pancreatic Neuroendocrine Tumors and Carcinoids (2000) (0)
980 EUTHYROID HIGH TOTAL T 4 , NORMAL T 3 SYNDROME (2003) (0)
99mTc-gastrins: Impact of (Glu)5-chain and NEP-inhibition on pharmacokinetics (2014) (0)
[(111In-DOTA)Lys0]Tate: effects of Lys0-Introduction on AR4-2J tumor and kidney uptake in SCID mice (2010) (0)
545 PEPTIDE RECEPTOR TARGETING IS SUPERIOR TO METABOLIC TARGETING FOR IN VIVO IMAGING OF HUMAN PROSTATE CANCER XENOGRAFTS (2010) (0)
In memoriam: Marion Hendriks-de Jong (2021) (0)
When is addition of dobutamine-atropine MIBI SPECT to echocardiography useful in risk stratificating patients with chest pain? (1995) (0)
Subject Index, Vol. 54, Supplement 1, 1993 (1993) (0)
1.53 The diagnostic accuracy of exercise stress 99m Technetium sestamibi SPECT imaging is not reduced in hypertensive patients (2001) (0)
Acute Coronary Disease Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction (2004) (0)
Biodistribution of [111In-DOTA0,trp8]SS-14 in sst2/3/5+-HEK tumor-bearing mice (2010) (0)
Peptide receptor therapy with 111IN-DTPA-octreotide (OC) (1997) (0)
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors. (2019) (0)
Breast Imaging with Radiolabeled Peptides (2020) (0)
The GRP receptor as target for molecular imaging of prostate cancer (2006) (0)
Blood measurements of Neuroendocrine Tumor (NET) transcripts and gene cluster analysis predict efficacy of PRRT (2017) (0)
Comparison of 1 ! 1 In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy 1 (2006) (0)
estimates for clinical translation (2016) (0)
761 Circulating Neuroendocrine Gene Transcripts Accurately Identify GEP-NETs, Are Decreased by Surgery and Predict Tumor Progression and Recurrence (2016) (0)
Degeneration and regeneration of tissues of the skeletal system (2010) (0)
More intense uptake of Lu-177-octreotate (Lu-tate) in neuroendocrine tumors compared to In-111-Octreotide does not predict the outcome, in contrast to decrease of tumor uptake of Lu-tate during Lu-tate therapy (2006) (0)
Pharmaceutical comprising somatostatin derivatives (1991) (0)
PL-5: DIAGNOSTIC AND THERAPEUTIC APPLICATION OF SOMATOSTATIN ANALOGS (1994) (0)
Reply (2007) (0)
New Clinical Studies with 177Lu-Labelled Somatostatin Analogs (2016) (0)
Organ and tumor dosimetry of Lu-177-DOTA-Tyr(3)-octreotate (Lu-TATE) and Y-90-DOTA-Tyr(3)-octreotide (Y-TOC): A preliminary study in 2 patients. (2002) (0)
Brief report An unusual case of multiple endocrine neoplasia type 1 and the role of '11 In-pentetreotide scintigraphy (1996) (0)
Localization of occult metastases in patients with medullary thyroid carcinoma by 99mTc-Demogastrin 2 scintigraphy (2012) (0)
Contents Vol. 80, 2004 (2005) (0)
Somatostatin receptor scintigraphy for the initial staging of Hodgkin's disease (1997) (0)
Preclinical study of a novel 99mTc-radiofolate with improved characteristics for folate receptor-positive tumor targeting (2007) (0)
After Acipimox Administration (2003) (0)
Safety of Dobutamine-AtropineStress Myocardial Perfusion Scintigraphy (2006) (0)
Title: Mtor Inhibitor Rad001 Promotes Metastasis in a Rat Model of Pancreatic Neuroendocrine (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Eric Paul Krenning?

Eric Paul Krenning is affiliated with the following schools: